Table 2.

Risk Factors For Post-PV MF And Leukemic Transformation

Risk Factor	Comments
Advanced Age	≥ 60 years old
Leukocytosis	WBC ≥15–30 × 109/L
JAK2 Allele Burden	Homozygous > Heterozygous
Non-Driver Mutations	Post PV MF: ASXL1, SRSF2, RUNX1, SF3B1, IDH1/2
	AML ASXL1,TP53, SRSF2, IDH1/2, RUNX1
Exposures to Therapies	Leukemogenic Risk Phosphorus-32(32P), Chlorambucil, Pipobroman
	No Leukemogenic Risk Hydroxyurea (controversial), Busulfan, *Erythropoiesis stimulating agents (ESAs), *Splenectomy

Note: *Not reproducible and confounded by severe underlying disease.